Neuroradiologists, Be Mindful of the Neuroinvasive Potential of COVID-19

M. Morris and V.M. Zohrabian

AJNR Am J Neuroradiol published online 30 April 2020
http://www.ajnr.org/content/early/2020/04/30/ajnr.A6551

This information is current as of August 20, 2024.
Neuroradiologists, Be Mindful of the Neuroinvasive Potential of COVID-19

The COVID-19 pandemic continues to have a far-reaching impact on nearly all aspects of society. First identified in December 2019 in Wuhan, the capital city of Hubei, China, COVID-19 is disseminated primarily via respiratory droplets and has the potential to cause severe respiratory distress in vulnerable patients, resulting in pneumonia, acute respiratory distress syndrome (ARDS), multiorgan dysfunction, and death. Although recent literature on the virus has centered on the respiratory manifestations of the disease, a multitude of studies during the past few decades have shown that several respiratory viruses, including coronaviruses (CoVs), have neuroinvasive potential, demonstrating the ability to spread from the respiratory tract to the CNS to trigger or exacerbate neurologic pathology as a result of direct viral replication in the CNS or overactive host immune response. This information is of interest to neuroradiologists, given that as the pandemic rages on, they may encounter sequelae of disease in the brain and spinal cord as these patients are imaged for neurologic symptoms.

First isolated in the mid-1960s, 6 types of CoVs, large-enveloped nonsegment positive-sense RNA viruses, are known to infect humans: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, Severe Acute Respiratory Syndrome-CoV (SARS), Middle East Respiratory Syndrome-CoV (MERS), and now, SARS-CoV-2 (COVID-19), a close relative of SARS. Most of these CoVs result in mild disease, with the exception of SARS and MERS, and most recently COVID-19, which may be lethal. Moreover, HCoV-229E, HCoV-OC43, SARS, and MERS have demonstrated neurotropism, or the ability to infect resident cells of the CNS (neuronal and glial). MERS and SARS have demonstrated the ability to invade human neuronal cells in vitro. Moreover, SARS, among numerous other CoV strains, has been found in the CSF of patients, as well as in neurons in situ per postmortem studies. It is known that both SARS and COVID-19 leverage the angiotensin-converting enzyme 2 (ACE-2) receptor for entry into host cells, though there is debate as to whether there are sufficient concentrations of this receptor in the CNS to explain their neurotropic nature.

There are 2 main candidate mechanisms by which respiratory viruses may infect the CNS: hematogenous or neuronal retrograde. In the hematogenous route, the virus may pass through the BBB by transcytosis across brain microvascular endothelial cells and pericytes by endocytic vesicles or, rather, directly infect endothelial or epithelial cells to pass across the BBB or blood-CSF barrier in the choroid plexus of the ventricular system, respectively. Alternatively, the virus could be transported intracellularly in a concealed manner by leukocytes. There is mixed evidence regarding the viability of the hematogenous route in the neuroinvasiveness of CoVs. On the one hand, it has been reported that SARS has the ability to directly infect the BBB epithelium, representing 1 avenue of hematogenous spread. Additionally, several strains of CoVs, including SARS, have shown the ability to infect multiple types of leukocytes both in vitro and in vivo. This feature represents a potential second avenue of hematogenous spread, akin to the “Trojan Horse” model exhibited by HIV, by which the virus is covertly introduced to the CNS by a host’s infected immune cells. However, evidence against the hematogenous route revolves around human postmortem in situ studies demonstrating the presence of SARS only in neurons and not other cell types of the brain, as was recently argued by Li et al.

In the neuronal retrograde route of CNS entry, the virus invades neurons in the periphery, such as olfactory receptor neurons, those of the trigeminal nerve that reside in the nasal cavity, or sensory fibers of the vagus nerve in the brain stem, and leverages active transport mechanisms to gain access to the CNS. The ability of SARS, MERS, and other CoVs to leverage this mechanism has been demonstrated in mouse models, via intranasal inoculation and subsequent infection of the olfactory bulb, as in Fig 1. Once in the CNS, some strains of CoVs have been shown to be able to propagate between neurons, possibly through synaptic transmission.

Several CoVs have demonstrated the potential for neurovirulence in both children and adults. While no direct causal link has been established, multiple strains of CoVs have been associated with chronic CNS diseases, such as multiple sclerosis and neurodegeneration, in addition to acute processes, such as encephalitis, acute flaccid paralysis, Guillain-Barre syndrome, acute disseminated encephalomyelitis (ADEM), focal seizures, and other neurologic syndromes, including hemorrhage and stroke. Clinical studies have begun to elucidate physiologic changes associated with acute CoV CNS infection, such as unique cytokine profiles, moreover, malfunction of the cardiorespiratory center in
The brain stem has been hypothesized to play a potential role in respiratory distress in both humans and mouse models. Although it is still fairly early in the COVID-19 pandemic, there are already reports of neurologic symptoms. In a study published in February this year in hospitalized patients with COVID-19 in Wuhan, China, the authors found that around one-third of patients had neurologic manifestations, most commonly dizziness and headache, though peripheral nervous system symptoms, primarily hypogeusia and anosmia, were also seen. A small number of patients experienced acute cerebrovascular injury (ischemic stroke, cerebral hemorrhage), loss of consciousness, and muscle injury. It is interesting that some patients developed hypogeusia or anosmia, perhaps in support of the retrograde neuronal route of CNS invasion in COVID-19 via the olfactory bulb or other sensory branches of cranial nerves.

Several older reports have incorporated imaging in the neurologic work-up of patients with CoV infections. In a 15-year-old previously healthy boy, CoV-OC43 was detected in the CSF and nasopharyngeal secretions by polymerase chain reaction, while MR imaging of the brain and spinal cord demonstrated findings characteristic of ADEM, with T2-weighted hyperintensities in white matter tracts of the brain, some of which enhanced after intravenous gadolinium administration, as well as in the spinal cord, which were nonenhancing, with follow-up imaging demonstrating improvement in these lesions. In a study of hospitalized children with CoV and acute encephalitis-like syndrome, half of patients who underwent MRI or CT showed abnormalities, such as in the temporal lobes in patients with seizures, in the periventricular regions in patients with headaches, and in the basal ganglia and thalami in patients with fever and/or vomiting. Moreover, in a study that incorporated imaging in 3 patients with MERS, brain MRI revealed widespread, bilateral T2-weighted hyperintense lesions in white matter and subcortical areas of the frontal, temporal, and parietal lobes; the basal ganglia; and corpus callosum, none of which showed gadolinium enhancement, which investigators attributed to ADEM, anoxic injury, and encephalitis, respectively. Most interestingly, meningeal enhancement has not been shown in brain MRI of patients with CoV infection, arguing against a hematogenous method of entry into the CNS.

Neuroradiologists will undoubtedly encounter increasing numbers of patients with COVID-19 in the course of daily practice. Therefore, they should be cognizant of the potential for CNS injury, either directly as the virus replicates in cells, or indirectly as host immune responses wage an all-out war. Furthermore, neuroradiologists should be wary of secondary impacts of COVID-19 on the CNS in severely ill patients, such as anoxic brain injury as a result of ARDS, cerebral hemorrhage as a result of thrombocytopenia, and disseminated intravascular coagulation, and air and fat emboli in patients with sepsis. As COVID-19 continues to spread across the globe, neuroradiologists should entertain this virus as a possible etiologic agent in patients with progressive or worsening CNS symptoms.

The possible imaging manifestations of CoV disease in the brain and spinal cord are varied, as shown by the aforementioned studies, and include injuries to both gray and white matter. In reading rooms, neuroimaging should be tailored to the clinical question while evaluating for complications such as ADEM, encephalitis, and Guillain-Barre syndrome, as reported in prior case series, whenever the clinical scenario can support such etiologies. Just as important, imaging should be reasonable and not excessive, keeping in mind that hospitalized patients with COVID-19 tend to be quite ill, so as to provide optimal patient care, preserve hospital resources, and minimize exposure of radiology staff, such as technologists and nurses, to the virus. With time and large-scale and rigorous investigations, hopefully the full spectrum of neuropathologies and exact mechanisms of injury in patients with COVID-19 will be uncovered.

REFERENCES


